SPRINT

When benefit exists but trade-offs matter

Input · the abstract you paste

SPRINT randomized 9,361 non-diabetic adults ≥50 years with elevated cardiovascular risk to an intensive systolic blood-pressure target (<120 mmHg) or standard (<140 mmHg). The intensive arm reduced the primary cardiovascular composite (HR 0.75) and all-cause mortality (HR 0.73), but at the cost of more intervention-related serious adverse events and acute kidney injury. The trial was stopped early and used unattended automated BP measurement.

For illustration only. TrialReviewer appraises evidence quality to inform professional judgment; it is not medical advice, and clinical decisions are made by the clinician.

This appraisal is generated by AI (based on clinical-epidemiology methods) to inform professional judgment; it does not replace expert human review.

Study type: open-label RCT (early-terminated) · N=9,361 · Median follow-up 3.26 y · Evidence level: Full text

Bottom Line

Appraisal confidenceB

In non-diabetic adults ≥50 at elevated CV risk, targeting SBP <120 mmHg reduced the cardiovascular composite and all-cause mortality compared with <140 mmHg. However, benefit must be weighed against increased intervention-related serious adverse events and the trial's unattended automated BP measurement context, which may not translate directly to routine clinic readings.

Large, NIH-funded, pre-registered RCT with independently adjudicated hard endpoints; one material downgrade (early termination + open-label) keeps it at B, short of A; the BP-measurement context mismatch must be translated before clinical thresholds apply.

PICO

P — Population

Adults ≥50, SBP 130–180, elevated CV risk, no diabetes / prior stroke (mean age 68; 28% ≥75)

I — Intervention

Intensive BP lowering, SBP target <120 mmHg

C — Comparison

Standard BP lowering, SBP target <140 mmHg

O — Outcome

Composite MACE (MI / ACS / stroke / HF / CV death); all-cause mortality

Key endpoints

Endpoint	Result	Direction
Primary composite (MACE)	HR 0.75 (0.64–0.89) · NNT 61	Favors intensive
All-cause mortality	HR 0.73 (0.60–0.90) · NNT 90	Favors intensive
CV death	HR 0.57 (0.38–0.85)	Favors intensive
Heart failure	HR 0.62 (0.45–0.84)	Favors intensive
MI / stroke (per-component)	HR 0.83 / 0.89 · not significant	Consistent but underpowered

Primary composite HR 0.75 (95% CI 0.64–0.89)

The CI excludes the null (1.0) — a statistically significant benefit.

Absolute effect — ARR / NNT / NNH

ARR

1.65%

primary composite (cumulative, 3.26 y)

NNT

primary · all-cause death NNT 90

NNH

varies by harm

AKI/renal failure ≈63; hypotension, syncope, and electrolyte events also increased.

SPRINT reports arm-specific rates, so ARR / NNT / NNH are all computable — benefit and harm quantified side by side, the textbook “benefit but trade-offs” case.

Methodology concerns

1
Open-label design and heart-failure ascertainment.
Why it matters：HF hospitalization is a semi-soft endpoint; admission thresholds can differ when assignment is known [Wood et al. 2008].
Impact：HF's contribution to the composite (HR 0.62) may be amplified; but the mortality benefit is not subject to this mechanism and independently supports the conclusion.
2
The trial was terminated early for benefit.
Why it matters：Trials stopped early for benefit can overestimate effect size [Bassler et al. 2010].
Impact：The relative benefit may be somewhat inflated, although the mortality benefit is consistent in direction.
3
Blood-pressure measurement context mismatch.
Why it matters：SPRINT used unattended automated office BP measurement; routine attended clinic measurement may not map directly onto the same SBP threshold [Drawz et al. 2014].
Impact：Do not translate <120 mmHg mechanically into all routine clinic BP settings.
4
Renal safety signal in non-CKD participants.
Why it matters：eGFR decline ≥30% HR 3.49 (2.44–5.10), 3.8% vs 1.1% (NNH 37).
Impact：3.26 y is too short to separate reversible hemodynamics from long-term renal injury; monitoring and individualized assessment are needed.
5
Cognitive / dementia endpoints not reported here.
Why it matters：Pre-specified but deferred to a separate analysis; intensive lowering carries a theoretical cerebral-hypoperfusion risk.
Impact：The gap limits full risk integration (later SPRINT-MIND supplied a partial answer).

Benefit – harm tradeoff

Benefit

Primary composite −25% and all-cause mortality −27% (NNT 61 / 90), driven independently by CV death and heart failure — not a soft-endpoint rescue.

Harm

More intervention-related SAEs (NNH 45), AKI (NNH 63), and eGFR decline in non-CKD patients (NNH 37) — mostly reversible and dose-managed.

Net clinical value

Net benefit remains (mortality benefit outweighs the SAE burden), but the renal signal and measurement mismatch demand individualized weighing — benefit exists, but trade-offs matter.

Why downgraded (GRADE)

Start: High (RCT)

−1 Risk of Bias

Open-label performance-bias risk for the HF hospitalization endpoint; early termination adds upward effect-size inflation [Bassler et al. 2010; Balshem et al. 2011].

Primary outcome (CV composite) · evidence quality: Moderate → appraisal confidence: B

Citations & references

In the full report every threshold judgment carries an inline [Author Year] citation. Sources for this example:

Bassler D et al. (2010). Stopping randomized trials early for benefit. JAMA; 303(12):1180–7.
Balshem H et al. (2011). GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol; 64(4):401–6.
Drawz PE et al. (2014). Intensive vs standard clinic-based hypertension management on ambulatory BP (SPRINT ABPM). Hypertension; 65(6):1340–6.
Wood AM et al. (2008). Are missing outcome data adequately handled? BMJ; 337:a1227.
Williamson JD et al. (2019). Intensive vs standard BP control on probable dementia (SPRINT MIND). JAMA; 321(6):553–61.

Start my own appraisal →